SECOND ANNUAL

Fluorescence-Guided Surgery Brain Tumor Symposium

DECEMBER 6, 2019

Icahn School of Medicine at Mount Sinai Leon and Norma Hess Center for Science and Medicine Bonnie M. Davis, MD and Kenneth L. Davis, MD Auditorium 1470 Madison Avenue New York, NY

Course Director

Constantinos G. Hadjipanayis, MD, PhD


Site Chair, Department of Neurosurgery, Mount Sinai Union Square Professor of Neurosurgery & Oncological Sciences
Director, Neurosurgical Oncology
Director Brain Tumor Nanotochnology

Director, Brain Tumor Nanotechnology Laboratory

Mount Sinai Health System

mssm.cloud-cme.com/FGS





Registered neurosurgeons will hear experts from both the U.S. and Europe discuss fluorescence-guided surgery. The goal is to equip our healthcare providers with the tools they need to provide optimum health care to their patients.

PROGRAM OBJECTIVES

Define the use of fluorescence-guided surgery (FGS) for gliomas to practicing neurosurgeons, discuss the use of FGS for different tumor types, and discuss the use of FGS in combination with other intraoperative visualization technologies.

WHO SHOULD ATTEND?

Neurosurgeons, Allied Health Professionals, Residents, and Fellows.

ACCREDITATION

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Icahn School of Medicine at Mount Sinai designates this live activity for the maximum of **8.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

VERIFICATION OF ATTENDANCE

Will be provided to all professionals.

COURSE LOCATION

The Bonnie M. Davis, MD and Kenneth L. Davis, MD Auditorium, 2nd Floor, 1470 Madison Avenue (between 101st and 102nd streets), New York, NY. Directions and parking:

www.icahn.mssm.edu/about/visiting.

ACCOMODATIONS

Discounted sleeping rooms can be reserved with our Hosing Manager, Denise Newman. Cell/text: 347-236-7181; phone: 718-835-4911; email: dnew229@aol.com.

SPECIAL NEEDS

The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require special accommodations, call the Office of CME at 212-731-7950.

7:00 am	Registration and Breakfast
7:30	Welcome and Symposium Overview Constantinos G. Hadjipanayis, MD, PhD
7:45	Introduction to Fluorescence-Guided Surgery (FGS) Constantinos G. Hadjipanayis, MD, PhD
8:15	Current and Future State of Fluorescence-Guided Surgery for Brain Tumors Walter Stummer, MD, PhD
9:00	5-ALA Fluorescence-Guided Surgery for High-Grade Gliomas Shawn Hervey-Jumper, MD
9:30	5-ALA Fluorescence-Guided Surgery for Low-Grade Gliomas Nader Sanai, MD
10:00	BREAK WITH EXHIBITORS
10:30	Microscope and Handheld Fluorescence-Guided Surgery of Brain Tumors David Roberts, MD
11:00	5-ALA for other CNS Tumors and Stereotactic Biopsies Georg Widhalm, MD, PhD
11:30	Use of Fluorescence-Guided Surgery and Intraoperative MRI (iMRI) lan Y. Lee, MD
12:00 pm	LUNCH & Fluorescence-Guided Surgery Simulation 1 (Seminar Room B) Walter Stummer, MD, PhD and Constantinos G. Hadjipanayis, MD, PhD
1:00	Second Window Indocyanine Green for Identification of Brain Tumors John Lee, MD
1:30	Use of Fluorescein for Brain Tumor Fluorescence-Guided Surgery Jeffrey Bruce, MD
2:00	Tozuleristide Fluorescence-Guided Surgery of Pediatric Brain Tumors Amy Lee, MD
2:30	Antibody-Labled Fluorophores (Cetuximab-IRDye800) for GBM Resection Gerald Grant, MD
3:00	BREAK WITH EXHIBITORS & Fluorescence-Guided Surgery Simulation 2 (Seminar Room A) Walter Stummer, MD, PhD and Constantinos G. Hadjipanayis, MD, PhD
4:00	5-ALA Photodynamic Therapy for GBM Nicolas Reyns, MD, PhD
4:30	Panel Discussion: How Do I Use Fluorescence-Guided Surgery in my Practice? All Faculty
5:00	Completion of Symposium

Faculty

Course Director

Constantinos G. Hadjipanayis, MD, PhD

Site Chair, Department of Neurosurgery, Mount Sinai Union Square Professor of Neurosurgery & Oncological Sciences Director, Neurosurgical Oncology Director, Brain Tumor Nanotechnology Laboratory Mount Sinai Health System



Jeffrey Bruce, MD

Vice-Chairman of Academic Affairs
Deptartment of Neurosurgery
Co-Director, Brain Tumor Center
Columbia University Irving Medical Center

Gerald Grant, MD

Professor of Neurosurgery Division Chief of Pediatric Neurosurgery Stanford University Medical Center

Shawn Hervey-Jumper, MD

Associate Professor of Neurological Surgery University of California, San Francisco

Amy Lee, MD

Associate Professor of Neurological Surgery Seattle Children's Hospital University of Washington School of Medicine

Ian Y. Lee, MD

Co-Director, Hermelin Brain Tumor Center Director, Spinal Neuro-Oncology Department of Neurosurgery Henry Ford Hospital

John Y.K. Lee, MD

Associate Professor Deptartments of Neurosurgery and Otolaryngology University of Pennsylvania

Nicolas Reyns, MD, PhD

Professor of Neurosurgery University of Lille Sciences and Technology Lille, France



David Roberts, MD

Professor of Neurosurgery and Neurology Geisel School of Medicine Dartmouth-Hitchcock Medical Center

Nader Sanai, MD

Najafi Professor of Neurological Surgery Director, Division of Neurosurgical Oncology Director, Ivy Brain Tumor Center Barrow Neurological Institute

Walter Stummer, MD, PhD

Professor and Chairman Department of Neurosurgery University of Munster Munster, Germany

Georg Widhalm, MD, PhD

Assistant Professor Department of Neurosurgery Medical University of Vienna Vienna, Austria

FACULTY DISCLOSURE

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

